Agenda
The program for RWE 2022 is below, with speakers being announced regularly, please watch this space!
At this year’s event, you can expect core themes including:
- Reimbursement and payer models
- Regulatory tools and fairness
- The impact of big data, artificial intelligence and machine learning
- Exploring quality, registries and patient-first practices
RWE 2022 will be an engaging and accessible event:
- The Collaboration and Mastery Zone will comprise panels and presentations, with ample time for questions and discussion, enabling participants to experience debates and learn about the latest developments.
- The Debate and Dialogue Zone will subvert the traditional conference, and create a space for roundtables, fishbowl conversations, creating an environment to share, build relationships, and collaborate on future projects.
DAY ONE – Wednesday 29 June 2022
08:15 | 09:00 | Registration, breakfast, coffee and exhibition | |
09:00 | 09:05 | Welcome Laura Dormer, Future Science Group |
|
09:05 | 09:15 | Opening remarks Conference chair |
|
09:20 | 09:50 | Opening keynote fireside chat: understanding the human angle – the impact of rare diseases: my story
Jean-Christophe Novelli |
|
09:50 | 10:35 | Regulator keynote 2025 vision: collaborating to enable use and establish value
|
|
10:30 | 11:05 | Morning coffee, speed networking and exhibition | |
COLLABORATION AND MASTERY ZONE | DEBATE AND DIALOGUE ZONE | ||
Understanding reimbursement | |||
11:05 | 11:35 | Gaining clarity on RWE and payer models across Europe: managing the uncertainty of approving and reimbursing drugs
Lotte Steuten, Office of Health Economics |
Two parallel sessions: Fishbowl session – “moving panel” with participants stepping in and out to keep conversation going and fresh ideas flowingHow has access to RWD informed care pathways for patients? Roundtable conversation – kickstarted with opening remarks, this concurrent conversation is designed to encourage debate and collaboration Using RWE to support cell and gene therapies
|
11:35 | 12:05 | Understanding the lifecycle approach to determining the value of treatments
Amr Makady, Janssen |
|
12:05 | 12:35 | RWE for HTA payer decisions: the rare diseases perspective
|
Fishbowl session: TBA
Roundtable conversation: Outcomes-based payment models |
12:35 | 13:05 | Economic modelling in rare diseases: how should we assess value?
Christian Hill, MAP BioPharma |
|
13:05 | 14:10 | Lunch and exhibition | |
COLLABORATION AND MASTERY ZONE | DEBATE AND DIALOGUE ZONE | ||
Achieving patient focus | |||
14:10 | 14:30 | Listen and learn: partnering with patient advocates and groups
|
Fishbowl session: Developing patient centrality in RWE
Roundtable conversation: Using RWD to identify patients eligible for clinical trials Moderator: Tim Williams, CPRD, MHRA |
14:30 | 15:00 | How do you share real-world patient data?
Andreas Hager, Patient Data Lawyer |
|
15:00 | 16:30 | Afternoon tea and exhibition | |
Registries: curse or cure? | |||
15:10 | 15:40 | Should you trust Trusted Research Environments? Why? Why not?
Susheel Varma, HDR UK |
Fishbowl session: Untapped opportunities in registries
Roundtable conversation: Developments in trial methodology
|
16:10 | 16:40 | How are registries learning and changing?
Sofie Terwel, European Blood and Marrow Transplant registry |
|
16:40 | 16:55 | Closing questions | |
17:00 | 18:30 | Drinks reception |
DAY TWO – Thursday 30 June 2022
08:15 | 09:00 | Registration, breakfast, coffee and exhibition | |
09:00 | 09:20 | Welcome address Laura Dormer, Future Science Group |
|
09:20 | 09:50 | Harnessing partnerships to unlock data and creative collaborative learning systems | |
09:50 | 10:35 | Accelerated regulatory approval in 2022 and beyond: managing uncertainty with the impact of Brexit and COVID
Panelists: Alexander Shacht, Veramed Leslie Galloway, Ethical Medicines Industry Group |
|
10:35 | 11:05 | Morning coffee, speed networking and exhibition | |
COLLABORATION AND MASTERY ZONE | DEBATE AND DIALOGUE ZONE | ||
Agility and collaboration | |||
11:05 | 11:35 | Achieving transparency in the generation and use of RWE
Richard White, Oxford PharmaGenesis |
Fishbowl session: Untapped opportunities in registries
Roundtable conversation: TBA |
11:35 | 12:05 | HTA-quality real world data – what quality is required?
Catia Proenca, Alira Health |
|
12:05 | 12:35 | Is it fair? Understanding the healthcare disparities and fair access to treatment | Fishbowl session: TBA Roundtable conversation: Data and the patient: are there novel ways of generating patient-centric data? |
12:35 | 13:05 | Opportunity for a sponsored feature, if you’re interested in filling this slot please contact our Business Development Director, Ian Law, at [email protected] | |
13:05 | 14:10 | Lunch and exhibition | |
COLLABORATION AND MASTERY ZONE | DEBATE AND DIALOGUE ZONE | ||
Impact of data quality and artificial intelligence | |||
14:10 | 14:40 | Title TBC: Leveraging EHRs for trial recruitment and management
Tim Williams, CPRD, MHRA |
Fishbowl session: TBA
Roundtable conversation: Who owns the data? How much are patients, the public and governments willing to share?
|
14:40 | 15:10 | Leveraging artificial intelligence and machine learning for data quality
Akrivia Health Speakers TBC |
Digital health, cognition and decentralized and virtual trials
|
15:10 | 15:40 | Afternoon tea, speed networking and exhibition | |
15:40 | 16:10 | How much uncertainty in the changing regulatory environment: what is the risk and benefit balance? | Fishbowl session: TBA Roundtable conversation: The challenges of data collection |
16:10 | 16:40 | Closing keynote fireside chat Topic: TBA |
|
16:40 | 17:00 | Closing keynote remarks Next steps in RWE and rare diseases |